Round Up

Five things for pharma marketers to know: Tuesday, November 15, 2016

Five things for pharma marketers to know: Tuesday, November 15, 2016

By

The CMS spent more on Harvoni than any other drug; Novartis considers selling Alcon; the EMA recommends approval of Lantus biosimilar

Five things for pharma marketers to know: Monday, October 31, 2016

Five things for pharma marketers to know: Monday, October 31, 2016

By

Shares decline on news drugmakers will limit price hikes; AstraZeneca said it will leave UK if country doesn't pay for new drugs; Astellas acquires Ganymed

Five things for pharma marketers to know: Wednesday, October 26, 2016

Five things for pharma marketers to know: Wednesday, October 26, 2016

By

Novartis CEO said pricing environment to worsen; Purdue Pharma offered PBM rebates to get around oxycodone prior authorization; Express Scripts subpoenaed

Five things for pharma marketers to know: Thursday, October 20, 2016

Five things for pharma marketers to know: Thursday, October 20, 2016

By

Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug

Five things for pharma marketers to know: Thursday, October 13, 2016

Five things for pharma marketers to know: Thursday, October 13, 2016

By

Aetna inks value-based deal with Merck in diabetes; new research claims co-pay cards increased drug spend; Xarelto data not affected by device

Five things for pharma marketers to know: Wednesday, October 12, 2016

Five things for pharma marketers to know: Wednesday, October 12, 2016

By

Valeant is under fire for another price hike; Novartis and Queen Latifah raise awareness about heart failure; critics take aim at co-pay programs

Five things for pharma marketers to know: Thursday, October 6, 2016

Five things for pharma marketers to know: Thursday, October 6, 2016

By

Xarelto may cause patients to have more serious bleeding episodes; devicemaker acquires Pfizer's infusion business; Theranos shutters laboratory operations

Five things for pharma marketers to know: Tuesday, September 27, 2016

Five things for pharma marketers to know: Tuesday, September 27, 2016

By

Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest

Five things for pharma marketers to know: Friday, September 2, 2016

Five things for pharma marketers to know: Friday, September 2, 2016

By

Hillary Clinton releases drug-pricing plan; patent for Teva's Copaxone is invalidated; Roche's immunotherapy extends life

Five things for pharma marketers to know: Wednesday, August 17, 2016

Five things for pharma marketers to know: Wednesday, August 17, 2016

By

AHIP study says half of orphan-drug usage is for non-orphan indications; Studies of GSK weight-loss pill underestimated side effects; ViiV starts HIV trial

Five things for pharma marketers to know: Monday, August 15, 2016

Five things for pharma marketers to know: Monday, August 15, 2016

By

Express Scripts does not disclose names of formulary board members; Endo withdrew abuse-deterrent formulation for opioid; BI to collect real-world data on Praxbind

OPINION

Email Newsletters